Edition:
India

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

89.15EUR
24 Nov 2017
Change (% chg)

€-0.65 (-0.72%)
Prev Close
€89.80
Open
€89.90
Day's High
€90.31
Day's Low
€88.67
Volume
541,451
Avg. Vol
565,778
52-wk High
€115.20
52-wk Low
€88.67

Latest Key Developments (Source: Significant Developments)

Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Orexigen Therapeutics Inc :Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt, Germany for contrave in Latin America.Orexigen Therapeutics - ‍Orexigen will receive an upfront payment and other potential regulatory and sales milestones, which have not been disclosed​.Orexigen Therapeutics Inc - ‍merck KGaA, Darmstadt, Germany will be responsible for all commercialization and regulatory activities ​.Orexigen Therapeutics Inc - ‍Orexigen will also be responsible for product supply​.Orexigen Therapeutics Inc - ‍under terms of agreement, Merck KGaA, Darmstadt, Germany will own marketing authorization in region​.  Full Article

BRIEF-Merck KGaA, Samsung Biologics sign MoU on strategic alliance
Wednesday, 1 Nov 2017 

Corrects company name in headline:Says MilliporeSigma signs memorandum of understanding (MoU) with Samsung Biologics for strategic alliance on biopharma manufacturing, biologics process development‍​.The new MoU is an extension of one signed in 2014 that encompasses a long-term supply agreement.  Full Article

GSK will look at Pfizer, Merck consumer assets if offered for sale
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - GlaxoSmithKline CEO Emma Walmsley tells reporters::as world leader in consumer healthcare, we will look at Pfizer consumer health.bulking up consumer is one option but top priority is boosting pharma pipeline.moving forward with Brexit contingency planning, would like to know about transition asap.needs clarity on Brexit implementation phase of at least 2 years.not thinking of any relocation out of UK as a result of brexit.would also look carefully at German Merck consumer assets.new pharma head Miels very focused on launch of 3 critical new products.happy to continue to work with Novartis on consumer health or take over stake if Novartis wants to sell.  Full Article

Merck KGaA: Canadian patent office to grant patent application for CRISPR technology
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - MERCK KGAA ::MERCK KGAA - CANADIAN PATENT OFFICE TO GRANT MERCK KGAA, DARMSTADT, GERMANY'S PATENT APPLICATION FOR CRISPR TECHNOLOGY.FIRST PATENT ALLOWANCE FOR COMPANY’S CRISPR TECHNOLOGY IN NORTH AMERICA‍​.  Full Article

Merck KGaA enters immuno-oncology collaboration with F-Star
Sunday, 4 Jun 2017 

June 4 (Reuters) - Merck KGaA :Strengthens immuno-oncology portfolio through expansion of F-star collaboration including LAG-3/PD-L1 bispecific antibody- new strategic collaboration to develop and commercialize bispecific immuno-oncology antibodies.Announced a new strategic collaboration with biopharmaceutical company F-star, Cambridge, UK, for development and commercialization of five bispecific immuno-oncology antibodies.Beyond these five bispecific antibodies, Merck KGgaA, Darmstadt, Germany, will have further rights to replace, as well as to add to these antibodies using F-Star's bispecific antibody platform.  Full Article

Merck KGaA says losing some market share in liquid crystals to new Chinese rivals
Thursday, 18 May 2017 

May 18 (Reuters) - Merck KGaA :CFO says seeing no signs of weakening demand at life science division.CFO says losing some market share in liquid crystals to new Chinese rivals.CFO says liquid crystal market share will level out over time at about 50-60 percent, down from clearly more than 60 percent over last 1-2 years.  Full Article

Transgene announces collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate the combination of TG4001 with Avelumab
Tuesday, 11 Oct 2016 

Transgene : Transgene announces collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate the combination of TG4001 with Avelumab in HPV-positive head & neck cancer in a phase 1/2 study . Transgene- this is an exclusive agreement between parties to study combination of these two classes of investigational agents in HPV-positive HNSCC .Transgene- phase I trial is expected to begin in France, with first patient expected to be recruited in H1 2017.  Full Article

Merck KGaA announces Isabel de Paoli new chief strategy officer
Friday, 23 Sep 2016 

Merck KGaA :Today announced that Isabel de Paoli has been appointed chief strategy officer effective Oct. 1, 2016.  Full Article

Moody's changes outlook on Merck KGAA's ratings to stable from negative; affirms ratings
Tuesday, 30 Aug 2016 

: Moody's changes outlook on Merck KGAA's ratings to stable from negative; affirms ratings . Moody's on Merck KGAA -Outlook change prompted by solid operating performance since assigning negative outlook in Dec 2014 due to Sigma-Aldrich deal . Moody's on Merck KGAA -Pace of deleveraging has been slightly behind expectations largely owing to delayed closing of the Sigma-Aldrich acquisition Source -http://bit.ly/2bXHwy2 ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Merck KGaA says fertility unit benefiting from production problems at 2 U.S. rivals
Thursday, 4 Aug 2016 

Merck KGaA media call : CEO on fertility business, benefiting from 2 competing products in U.S. held back by production problems . CEO says unclear how long positive effect will last because production of one rival fertility product has resumed . CEO says will file for first avelumab approval in U.S. at end-Q3, in Europe towards year-end . CEO says currently have no active plans to divest any businesses, though constantly reviewing our portfolio . CFO says acquisitions worth more than 500 million eur not on the agenda for next 2 years Further company coverage: [MRCG.DE] ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;)).  Full Article

BRIEF-Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt

* Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt, Germany for contrave in Latin America